Literature DB >> 12835093

Effects of clonidine and alpha-adrenoceptor antagonists on motor activity in DSP4-treated mice II: interactions with apomorphine.

A Fredriksson1, T Archer.   

Abstract

Adult mice were administered either the noradrenaline (NA) neurotoxin, N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) or distilled water (control), 10-12 days before motor activity testing, and 6 h before testing all the mice were administered reserpine (10 mg/kg), the monoamine-depleting agent. The interactive effects of (I) clonidine, the alpha(2)-adrenoceptor agonist, with the dopamine (DA) agonist, apomorphine, and the alpha(2)-antagonist, yohimbine, and (II) with either yohimbine or the alpha(1)-antagonist, prazosin, upon motor behaviour in activity test chambers were studied in reserpinized DSP4-treated and control mice. It was shown that apomorphine (3 mg/kg) increased locomotor and total activity in both reserpinized DSP4-treated and control mice but the effect was attenuated in the DSP4 mice. Co-administration of clonidine (3 mg/kg) with apomorphine potentiated the effects of apomorphine on motor activity and this effect was enhanced markedly by DSP4 pretreatment. Yohimbine (10 mg/kg) antagonized the motor activity-stimulating effects of apomorphine in both DSP4-treated and control mice. Co-administration of clonidine with apomorphine, following yohimbine, restored motor activity levels to those obtained in the absence of yohimbine and this effect upon locomotor activity was enhanced by DSP4 pretreatment. The effects of clonidine on motor activity were enhanced by NA-denervation. Prazzosin (3 mg/kg) enhanced the locomotor activity of both reserpinized DSP4-treated and control mice after the initial 30-min period but was not affected by DSP4 treatment. Analysis of post-decapitation convulsions (PDCs) indicated loss of the reflex by DSP4 pretreatment. Reserpine pretreatment abolished the initial, exploratory phase (30 min) of motor activity. These results demonstrate interactions between NA and DA systems that may bear eventual relevance to neurologic disorders such as parkinsonism.

Entities:  

Year:  2000        PMID: 12835093     DOI: 10.1007/bf03033255

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  49 in total

1.  Alpha 2-adrenergic sensitivity in Parkinson's disease.

Authors:  M Berlan; O Rascol; J Belin; J P Moatti; A Rascol; J L Montastruc
Journal:  Clin Neuropharmacol       Date:  1989-04       Impact factor: 1.592

Review 2.  Chemical neurotoxins as denervation tools in neurobiology.

Authors:  G Jonsson
Journal:  Annu Rev Neurosci       Date:  1980       Impact factor: 12.449

3.  Modulation of catecholamine release by alpha 2-adrenoceptors and I1-imidazoline receptors in rat brain.

Authors:  J J Meana; M Herrera-Marschitz; M Goiny; R Silveira
Journal:  Brain Res       Date:  1997-01-09       Impact factor: 3.252

4.  The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice.

Authors:  M Carlsson; A Svensson
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

5.  Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice.

Authors:  M Marien; M Briley; F Colpaert
Journal:  Eur J Pharmacol       Date:  1993-06-04       Impact factor: 4.432

6.  Potentiation of dopamine-dependent locomotion by clonidine in reserpine-treated mice is restricted to D2 agonists.

Authors:  M S Starr; B S Starr
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1994

7.  Norepinephrine-induced plasma dopamine decrease in man: pharmacological evidence of the involvement of alpha 2-adrenoceptors.

Authors:  N R Musso; R Gianrossi; C Vergassola; A Pende; A Ioverno; G Galbariggi; G Lotti
Journal:  J Hypertens       Date:  1992-09       Impact factor: 4.844

8.  Evidence for a selective brain noradrenergic involvement in the locomotor stimulant effects of amphetamine in the rat.

Authors:  S O Ogren; T Archer; C Johansson
Journal:  Neurosci Lett       Date:  1983-12-30       Impact factor: 3.046

9.  Norepinephrine-mediated suppression of apomorphine-induced aggression and locomotor activity in the rat amygdala.

Authors:  O Pucilowski; E Trzaskowska; W Kostowski; L Valzelli
Journal:  Pharmacol Biochem Behav       Date:  1987-02       Impact factor: 3.533

10.  DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine)--a useful denervation tool for central and peripheral noradrenaline neurons.

Authors:  G Jonsson; H Hallman; F Ponzio; S Ross
Journal:  Eur J Pharmacol       Date:  1981-06-19       Impact factor: 4.432

View more
  5 in total

1.  Influence of noradrenaline denervation on MPTP-induced deficits in mice.

Authors:  T Archer; A Fredriksson
Journal:  J Neural Transm (Vienna)       Date:  2005-12-16       Impact factor: 3.575

2.  Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurochem Res       Date:  2007-08-12       Impact factor: 3.996

3.  Postnatal iron overload destroys NA-DA functional interactions.

Authors:  A Fredriksson; T Archer
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

4.  The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?

Authors:  J Srinivasan; Werner J Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-29       Impact factor: 3.000

5.  The involvement of noradrenergic mechanisms in the suppressive effects of diazepam on the hypothalamic-pituitary-adrenal axis activity in female rats.

Authors:  Dubravka Švob Štrac; Dorotea Muck-Šeler; Nela Pivac
Journal:  Croat Med J       Date:  2012-06       Impact factor: 1.351

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.